Drug Development – Levine Media Group

Bio Usawa Announced an Agreement With Pacific Environmental Technologies to Design, Build, and Deploy State-of-the-Art, Modular Biomanufacturing Units

Bio Usawa, Inc., a biopharmaceutical company based in San Francisco, Kigali, and Nairobi, committed to expanding access to life-saving biologics in Africa and underserved regions, today announced an agreement with Pacific Environmental Technologies, Inc., a global leader in cleanroom facility design and construction, to design, build, and deploy state-of-the-art, self-contained modular biomanufacturing units. Read here.

White Paper Make Case for Early and Often Participation of Patient Advocates in Discovery and Development

Levine Media Group worked with the Global Genes Corporate Alliance to develop a white paper that argues that rare disease drug devleopers could save time, money, and produce better therapies by engaging with the patient community early and often in the drug development process. Download here.

Bio Usawa Appoints Dr. Patrick Lukulay as Chief Operating Officer

SAN FRANCISCO and KIGALI, Rwanda, Feb. 26, 2025 (GLOBE NEWSWIRE) — Bio Usawa, Inc., a pioneering biotechnology company dedicated to developing high-quality, affordable monoclonal antibodies in Africa, appointed Dr. Patrick Lukulay as its Chief Operating Officer. Read here.

Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy

SAN FRANCISCO and KIGALI, Rwanda, Dec. 17, 2024 (GLOBE NEWSWIRE) — Bio Usawa, Inc., a leading biotechnology company committed to delivering affordable and accessible monoclonal antibody-based therapies for cancer, ophthalmic, autoimmune, and infectious diseases in Africa, has named Mr. Eric Karikari-Boateng its Head of Global Regulatory Strategy. Read here.

Bio Usawa and Rwandan Government Sign a Memorandum of Understanding to Manufacture Affordable Biologics in Africa

SAN FRANCISCO and KIGALI, Rwanda, Nov. 21, 2024 (GLOBE NEWSWIRE) — Bio Usawa and the Rwanda Development Board have partnered to establish Rwanda’s first manufacturing plant for affordable treatments for serious eye diseases like diabetic macular edema. Read here.

Looking for the Common in Rare

Levine Media Group’s Daniel Levine moderates this panel at the 2024 Rare Advocacy Summit with Simon Frost, CEO and Co-founder, Tiber Capital Group; Karmen Trzupek, Senior Director, Scientific Programs, Global Genes; Joni Rutter, Ph.D., Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH). You can view it here.

Overcoming the Valley of Death in Research

Levine Media Group’s Daniel Levine moderates this panel at the 2024 Rare Advocacy Summit with Sharie Haugabook, Ph.D., Senior Project Manager and Drug Development Lead, Therapeutics for Rare and Neglected Disorders (TRND) National Institutes of Health (NIH); Christopher Hopkins, Ph.D., CEO, Devine Bio; Michael Hund, CEO, EB Research Partnership; and Yael Weiss, Ph.D., CEO, Mahzi […]